National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Daratumumab is indicated in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.


NCPE Assessment Process Complete
Rapid review commissioned 02/06/2020
Rapid review completed 17/07/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab compared with the current standard of care.